Divisive Teva-Merck IP Ruling Stays Out Of Supreme Court
The U.S. Supreme Court on Monday refused to weigh in on a dispute over a Merck & Co. Inc. patent for brain tumor treatment Temodar that sharply divided the Federal Circuit...To view the full article, register now.
Already a subscriber? Click here to view full article